Story perspectives

Moderna, Merck Report Phase 3 Results: 50% Risk Reduction

9/7/2026

Summary

Story summary

Moderna and Merck reported positive Phase 3 results for a personalized mRNA melanoma vaccine.
Dr. Ryan Sullivan reported patients receiving the vaccine showed reduced tumor spread versus controls.
Sullivan also noted fewer recurrences, indicating roughly a 50% reduction in cancer risk.
Investors are rebranding cancer vaccines as individual therapies after public skepticism.
Experts expect broader pharma interest and new mRNA vaccines targeting KRAS, HPV, despite a 10-15-year development horizon.

1 of 1

Story summary

Moderna and Merck reported positive Phase 3 results for a personalized mRNA melanoma vaccine.
Dr. Ryan Sullivan reported patients receiving the vaccine showed reduced tumor spread versus controls.
Sullivan also noted fewer recurrences, indicating roughly a 50% reduction in cancer risk.
Investors are rebranding cancer vaccines as individual therapies after public skepticism.
Experts expect broader pharma interest and new mRNA vaccines targeting KRAS, HPV, despite a 10-15-year development horizon.